MetaCap

Corcept Therapeutics (CORT) vs Cytokinetics (CYTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Corcept Therapeutics (CORT) has outperformed Cytokinetics (CYTK) over the past year, losing 17.7% versus a loss of 22.4%. Over five years, CORT leads with a +196.0% price change compared with +30.1% for CYTK. Cytokinetics is the larger company by market cap ($7.07 billion vs $6.96 billion), about 1.0 times the size.

Corcept Therapeutics converts more of its revenue into profit, with a net margin of 13.1% versus -891.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CORT-17.69%CYTK-22.40%
+66%+1%-64%
Nov 21, 20251 yearNov 20, 2026
CORT+178.18%CYTK+24.28%
+458%+203%-51%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CORT versus CYTK key metrics
MetricCORTCYTK
Share price$63.62$50.78
Market cap$6.96B$7.07B
1-day change-2.09%-1.32%
YTD return+82.82%-20.08%
1-year return-17.69%-22.40%
5-year return+196.04%+30.11%
P/E ratio (TTM)47.83—
Forward P/E12.77—
EPS (TTM)$1.33$-6.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$761.41M$88.04M
Revenue growth (YoY)+12.79%+376.56%
Net income (latest FY)$99.65M$-784.96M
Gross margin98.30%—
Operating margin5.88%-695.44%
Net margin13.09%-891.60%
52-week high$126.38$88.31
52-week low$28.66$50.32
Distance from 52-week high-49.66%-42.50%
Analyst consensusbuystrong_buy
Avg. price target upside+124.14%+115.48%
Average volume1.26M2.02M
Shares outstanding109.44M139.30M
Employees730673
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Corcept Therapeutics is more profitable, keeping 13.1 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
  • Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +12.79%).

About Corcept Therapeutics

CORT stock →

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees

About Cytokinetics

CYTK stock →

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees

CORT vs CYTK FAQ

Which is bigger, Corcept Therapeutics or Cytokinetics?

Cytokinetics (CYTK) is larger, with a market capitalization of $7.07B compared with $6.96B for Corcept Therapeutics (CORT).

Which stock has performed better over the past year, CORT or CYTK?

CORT returned -17.69% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.

Are Corcept Therapeutics and Cytokinetics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons